Acute promyelocytic leukemia presenting with central nervous system involvement: a report of 2 cases.
Central nervous system (CNS) involvement in acute promyelocytic leukemia (APL) is rare, and the presence of CNS symptoms at the time of diagnosis of APL is even rarer. We report 2 cases of APL presenting with CNS involvement. A 43-yr-old woman presented with easy bruising and stuporous mentality. Her complete blood count (CBC) revealed leukocytosis with increased blasts. Bone marrow (BM) analysis was carried out, and the diagnosis of APL was confirmed. This was done by cytogenetic analysis and demonstration of PML-RARα rearrangement by reverse transcriptase PCR in the BM cells. A lumbar puncture was performed to investigate the cause of her stuporous mentality, and her cerebrospinal fluid (CSF) analysis revealed 97% leukemic promyelocytes. Despite systemic and CNS therapy, she died due to septic shock by infection and rapid disease progression only 3 days after her admission. Another patient, a 3-yr-old girl, presented with easy bruising and epistaxis, and her CBC showed pancytopenia with increased blasts. BM studies confirmed APL. Quantitative PCR for PML-RARα in the BM cells revealed a PML-RARα/ABL ratio of 0.33 and CSF analysis revealed 9.5% leukemic promyelocytes (2 of 21 cells). She received induction chemotherapy and intrathecal therapy and achieved complete remission (CR) in the BM and CNS. She has been maintained in the CR status for the past 31 months. Thus, patients with APL must be evaluated for CNS involvement if any neurological symptoms are present at the time of diagnosis.
Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Misuk
M
Ji
Hyun-Sook
HS
Chi
Seongsoo
S
Jang
Chan-Jeoung
CJ
Park
Jung-Hee
JH
Lee
Jong Jin
JJ
Seo
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000378:metabolism / Q000473:pathology; D002490:Central Nervous System / Q000473:pathology; D002675:Child, Preschool; D003288:Contusions / Q000209:etiology; D004844:Epistaxis / Q000209:etiology; D005260:Female; D042381:Granulocyte Precursor Cells / Q000473:pathology; D006801:Humans; D007621:Karyotyping; D015473:Leukemia, Promyelocytic, Acute / Q000134:cerebrospinal fluid* / Q000188:drug therapy / Q000473:pathology; D015514:Oncogene Proteins, Fusion / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013129:Spinal Puncture; D014057:Tomography, X-Ray Computed; D014212:Tretinoin / Q000627:therapeutic use
D000970:Antineoplastic Agents; D015514:Oncogene Proteins, Fusion; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014212:Tretinoin
Leuk Lymphoma. 1999 Apr;33(3-4):219-29
10221502
J Neurooncol. 2006 Aug;79(1):73-5
16718520
J Korean Med Sci. 2004 Apr;19(2):311-4
15082912
Blood. 1995 Aug 15;86(4):1540-7
7632962
Pediatr Blood Cancer. 2009 Jan;52(1):11-3
18816805
Blood. 2009 Feb 26;113(9):1875-91
18812465
Cancer. 1987 Jan 1;59(1):94-8
3466663
Leuk Lymphoma. 2000 Sep;39(1-2):213-5
10975402
Expert Opin Pharmacother. 2003 Aug;4(8):1379-92
12877645
Pediatr Blood Cancer. 2010 Apr;54(4):603-5
19998465
Int J Hematol. 2009 May;89(4):489-496
19340529
Haematologica. 1988 Jan-Feb;73(1):71-3
3131209
Haematologica. 2009 Sep;94(9):1242-9
19608685
Bone Marrow Transplant. 2003 Oct;32(8):843-6
14520432
Leukemia. 2006 Jan;20(1):35-41
16307026